NNC0519-0130
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.
Novo Nordisk · Phase 1 · Completed · Enrollment 161
Participants reaching threshold, %
Source: Cited trial source. The denominator is the source figure, when it states one.
No selected arm reports a responder percent.
Show as table
| Arm | ≥5% | ≥10% | ≥15% | ≥20% |
|---|---|---|---|---|
| Single ascending dose (SAD) part | n/r | n/r | n/r | n/r |
| Multiple ascending dose (MAD) QD part | n/r | n/r | n/r | n/r |
| Type 2 diabetes (T2D) part | n/r | n/r | n/r | n/r |
| MAD QW part | n/r | n/r | n/r | n/r |
Not shown
- Single ascending dose (SAD) part: endpoint not reported
- Multiple ascending dose (MAD) QD part: endpoint not reported
- Type 2 diabetes (T2D) part: endpoint not reported
- MAD QW part: endpoint not reported